Kami Maddocks, MD, Hematology, Columbus, OH, Ohio State University Wexner Medical Center

KamiJ.MaddocksMD

Hematology Columbus, OH

Assistant Professor, Internal Medicine, Ohio State University College of Medicine

Dr. Maddocks is on Doximity

As a Doximity member you'll join over a million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Maddocks' full profile

Already have an account?

Education & Training

  • Ohio State University Hospital
    Ohio State University HospitalFELLOWSHIP
  • Mayo School of Graduate Medical Education
    Mayo School of Graduate Medical EducationRESIDENCY
  • Sanford School of Medicine of the University of South Dakota
    Sanford School of Medicine of the University of South DakotaMEDICAL_SCHOOL

Certifications & Licensure

  • OH State Medical License
    OH State Medical License 2008 - 2022
  • MN State Medical License
    MN State Medical License 2006 - 2008
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Update on Mantle Cell Lymphoma  
    Kami Maddocks, MD, Blood

Abstracts/Posters

  • Subgroup Analyses from L-Mind, a Phase II Study of Tafasitamab (MOR208) Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Kami J. Maddocks, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of...
    Kami J. Maddocks, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma
    Kami J. Maddocks, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Join now to see all

Lectures

  • Emerging Paradigms to Address Unmet Needs in Relapsed/Refractory DLBCL 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Update of the single-arm phase II L-MIND study of MOR208 + lenalidomide (LEN) in relapsed/refractory diffuse large B-cell lymphoma (R-R DLBCL): Response rates in patie... 
    2019 ASCO Annual Meeting - 6/1/2019
  • Single-Arm Phase II Study of MOR208 Combined with Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: L-Mind 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

  • Comorbidities and Role of R-CHOP in DLBCL
    Comorbidities and Role of R-CHOP in DLBCLFebruary 07, 2020
  • Potential Ibrutinib Resistance Mechanisms Identified in CLL
    Potential Ibrutinib Resistance Mechanisms Identified in CLLMarch 20, 2015

Hospital Affiliations